You are here:

enoxaparin (Clexane)


Following a full submission

enoxaparin (Clexane) is accepted for use within NHS Scotland for the treatment of acute ST-segment elevation myocardial infarction (STEMI) including patients to be managed medically or with subsequent percutaneous coronary intervention (PCI) in conjunction with thrombolytic drugs (fibrin or non-fibrin specific).

In clinical studies using a median of seven days of enoxaparin treatment, enoxaparin demonstrated a reduction in death or non-fatal MI compared to unfractionated heparin.

Drug Details

Drug Name: enoxaparin (Clexane)
SMC Drug ID: 380/07
Manufacturer: Sanofi-Aventis
Indication: Myocardial infarction with ST-segment elevation (STEMI).
BNF Category:
Sub Category: 2.8 Anticoagulants and protamine
Submission Type: Full submission
Status: Accepted
Date Advice Published: 13 July 2009